BMC Pulmonary Medicine · 2015 · 63 citations · 10 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyPulmonary Function TestingPulmonologyChronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease PharmacotherapyCombination Inhaler TherapyInhalation TherapyObstructive Lung DiseaseRespiratory DiseaseBeta2-adrenergic Agonist TherapyChronic Obstructive Pulmonary Disease Exacerbation TreatmentChronic Obstructive Pulmonary Disease Maintenance TherapyForced Expiratory Volume AssessmentLong-acting Bronchodilator TherapyLong-acting Muscarinic Antagonist CombinationsLong-acting Muscarinic AntagonistsLung Function Testing
BACKGROUND: Umeclidinium (UMEC; long-acting muscarinic antagonist) plus vilanterol (VI; long-acting beta2 agonist [LABA]) and the LABA/inhaled corticosteroid fluticasone propionate/salmeterol (FP/SAL) are approved maintenance treatments for chronic obstructive pulmonary disease (COPD). This 12-week, multicentre, double-blind, parallel-group, double-dummy study compared the efficacy and safety of these treatments in symptomatic patients with moderate-to-severe COPD with no exacerbations in the year prior to enrolment. METHODS: Patients (n = 717) were randomised 1:1 to once-daily UMEC/VI 62.5/25 mcg or twice-daily FP/SAL 500/50 mcg. Endpoints included 0-24 h weighted mean (wm) forced expiratory volume in 1 s (FEV1) (Day 84; primary), trough FEV1 (Day 85; secondary), other lung function endpoints, symptoms, quality of life (QoL) and safety. RESULTS: Improvements with UMEC/VI versus FP/SAL were 0.080 L (95 % confidence interval: 0.046-0.113; wmFEV1) and 0.090 L (0.055-0.125; trough FEV1) (both p < 0.001). UMEC/VI statistically significantly improved all other lung function measures versus FP/SAL. Both treatments demonstrated a clinically meaningful improvement in symptoms (Transition Dyspnoea Index ≥1 unit) and QoL (St George's Respiratory Questionnaire Total score ≥4 unit decrease from baseline) over 12 weeks. The incidence of adverse events was 28 % (UMEC/VI) and 29 % (FP/SAL); nasopharyngitis and headache were most common. CONCLUSIONS: Once-daily UMEC/VI 62.5/25 mcg over 12 weeks resulted in significant and sustained improvements in lung function versus twice-daily FP/SAL 500/50 mcg in patients with moderate-to-severe COPD and with no exacerbations in the year prior to enrolment. TRIAL REGISTRATION: NCT01822899 Registration date: March 28, 2013.
10
Bartolomé R. Celli, Nicola E. Thomas, Julie A. Anderson et al. · American Journal of Respiratory and Critical Care Medicine · 2008 · 746 citations
Christine Jenkins, Paul Jones, Peter M.A. Calverley et al. · Respiratory Research · 2009 · 344 citations · Full text
Claus Vogelmeier, Eric Bateman, John Pallante et al. · The Lancet Respiratory Medicine · 2012 · 315 citations